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Glioblastoma multiforme (GBM) is the most common and 
malignant primary brain tumor. The median survival time is 
14.6 months from time of diagnosis, in spite of aggressive 
surgery, radiation therapy and chemotherapy. Only 3 to 5% of 
patients survive more than three years. Recurrence of GBM is 
nearly universal, confers a dismal prognosis with a 6-months 
progression free survival (6M-PFS) rate of 15% to 21% and a 
median survival of 6.2 months. Advancements in the past 
decades have not significantly increased the overall survival 
of patients with this disease. GBM has been demonstrated 
NK-1 receptor system and Substance P can be used as a 
ligand for targeted therapy. Alpha emitter, like 213Bi offers 
the new potential for selective irradiation of tumors, with 
minimizing damage to adjacent tissue.  
Material and methods: 21 patients with primary recurrent 
glia tumor IV after standard therapy were included in the 
study during two years. Following intracavitary or 
intratumoral insertion of 1-2 catheter systems, patients were 
treated with 1–8 doses of 2 GBq 213Bi-DOTA-Substance P (213Bi-
SP) in intervals of 2 months. 68Ga-DOTA-Substance P (68Ga-SP) 
was co-injected with the therapeutic doses to assess 
biodistribution using PET/CT. Therapeutic response was 
monitored with MRI. Study was approved by the ethical 
committee of the Medical University of Warsaw. 
Results: Treatment with activity up to 13 GBq 213Bi-SP was 
tolerated well with only mild transient adverse reactions: in 
1 patient transient increase of focal neurological symptoms 
and in 3 patients episodes of epileptic seizures several days 
after treatment. PET/CT imaging showed high retention of 
the radiolabeled peptide at the tumor site.  
Out of 21 evaluable patients, 17 progressed within the 
follow-up period, 5 of them are alive at the end of follow-up. 
Four patients were excluded from evaluation due to lack of 
data. Median progression free survival was 3.7 months, with a 
6 months progression free survival rate of 19% . The median 
overall survival from the first diagnosis was 25.2 months, and 
from the start of 213Bi-SP was 6.5 months. Follow up of 
therapeutic responses and toxicity is continued and patient 
recruitment is ongoing. Busk 
 
Conclusions: Treatment of recurrent GBM with 213Bi-SP is safe 
and well tolerated. Targeted alpha therapy with 213Bi-SP may 
evolve as a promising novel option for treatment of recurrent 
GBM. 
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A high-resolution silicon detector probe, in coincidence with 
a conventional  
PET scanner, is expected to provide images of higher spatial 
resolution than those achievable using the scanner alone, due 
to the finer pixelization of the probe detector[1]. A PET-
probe prototype is being developed utilizing this principle 
[2]. The system includes a probe consisting of ten layers of 
silicon detectors, each a 80×52 array of 1×1×1 mm3 pixels, to 
be operated in coincidence with a modern clinical PET 
scanner. Detailed simulation studies of this system have been 
performed to assess the effect of the additional probe 
information on the quality of the reconstructed images.  
Using the Monte-Carlo simulation package GATE, a grid of 
point sources was simulated to study the contribution of the 
probe to the system resolution at different locations over the 
field of view (FOV). A resolution phantom was used to 
demonstrate the effect on image resolution for two probe 
positions. A homogeneous source distribution with hot and 
cold regions was used to demonstrate that the localized 
improvement in resolution does not come at the expense of 
the overall quality of the image. An imaging study using 
experimental probe data was also performed. The list-mode 
maximum likelihood–expectation maximization (ML–EM) 
algorithm[3] was used for image reconstruction in all cases.  
As expected, the point spread function of the PET-probe 
system was found to be non-isotropic and vary with position, 
offering improvement in specific regions. An increase in 
resolution, of factors of up to 2, was observed in the region 
close to the probe. Images of the resolution phantom showed 
visible enhancement in resolution when including the probe 
in the simulations, as can be seen in figure 1. The image 
quality study demonstrated that contrast and spill-over ratio 
in other areas of the FOV were not sacrificed for this 
enhancement. The improvement in resolution when using the 
Si detector probe was also observed using the experimental 
prototype. In this context, previously unrecoverable features 
in a resolution phantom could be resolved when probe data 
was included during image reconstruction. Remaining 
challenges in developing the PET-probe system include 
overcoming the limitations imposed by the timing 
performance of the Si detectors and more detailed system 
modeling in image reconstruction.    
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Figure 1: Images of the resolution phantom reconstructed 
using data from the probe and from the scanner alone. The 
probe is located to the right of the image, in close proximity 
to the phantom.  The phantom features are 4.8, 4.0, 3.2, 2.4, 
1.6 and 1.2 mm in diameter. Pixels are 1 × 1 × 1 mm3 
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Positron emission tomography is so far the only method for 
in-vivo dose delivery verification in hadron therapy that is in 
clinical use. PET imaging during irradiation maximizes the 
number of detected counts and minimizes washout. In such a 
scenario, also short-lived positron emitters will be observed. 
As very little is known on the production of these nuclides, 
we determined which ones are relevant for proton therapy 
treatment verification. 
In order to be relevant, nuclides have to be produced close 
to the distal edge and thus at rather low proton energy. 
Therefore we measured the integral production of short-lived 
positron emitters in the stopping of 55 MeV protons in 
carbon, oxygen, phosphorus and calcium. The experiments 
were performed at the irradiation facility of the AGOR 
cyclotron at KVI-Center for Advanced Radiation Technology, 
University of Groningen. The positron emitters were 
identified based on their half-life. In order to do this, the 
proton beam was pulsed, i.e. delivered as a succession of 
beam-on and beam-off periods, and the time evolution of the 
511 keV positron annihilation photons was recorded. A half-
life analysis of the beam-off period allowed to determine the 
production rates of separate nuclides. The 511 keV photons 
were detected by a germanium clover detector [1]. A 
correction for the escape of positrons from the target, 
determined via Monte Carlo simulations, was applied. 
In the stopping of 55 MeV protons, the most copiously 
produced short-lived nuclides and their production rates 
relative to the relevant long-lived nuclides are: 12N (T1/2 = 
11 ms) on carbon (9% of the 11C production), 29P (T1/2 = 4.1 
s) on phosphorus (20% of the 30P production) and 38mK (T1/2 
= 0.92 s) on calcium (113% of the 38gK production). No short-
lived nuclides are produced on water (i.e. oxygen). The 
experimental production rates are used to calculate the 
production on PMMA and a representative set of 4 tissue 
materials. [fig. 1] The number of decays per 55 MeV proton 
stopped in these materials, integrated over an irradiation, is 
calculated as function of the duration of the irradiation. The 
most noticeable result is that for an irradiation in (carbon-
rich) adipose tissue, 12N will dominate the PET image up to 
an irradiation duration of 70 s. On bone tissue, 15O 
dominates over 12N after 8-15 s (depending on the carbon-to-
oxygen ratio). Considering nuclides created on phosphorus 
and calcium, the short-lived ones provide 2.5 times more 
decays than the long-lived ones during a 70 s irradiation. 
Bone tissue will thus be better visible in beam-on PET 
compared to PET imaging after an irradiation. 
The results warrant detailed investigations into the energy-
dependent production of 12N, 29P and 38mK and their effect 
on PET imaging during proton irradiations. 
 
Figure 1: Number of decays of PET nuclides per 55 MeV 
proton stopped and integrated over an irradiation, as 
function of the duration of the irradiation for adipose, 
skeletal muscle, compact bone and cortical bone tissue. 
Short-lived nuclides are shown with solid lines, long-lived 
ones with dashed lines 
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Positron emission tomography is so far the only method for 
in-vivo dose delivery verification in hadron therapy that is in 
clinical use. A PET scanner placed in the treatment position 
(in-situ) will be able to obtain the highest number of counts, 
as it minimizes the decay of the positron emitting nuclei 
before the scan is started as well as reduces the effect of 
biological washout. We investigated the influence of the scan 
protocol, i.e. the moment when a scan in done in relation to 
the treatment delivery, on the ability to measure 
unacceptable deviations from the treatment plan. 
We developed a Geant4-based Monte-Carlo framework for 
proton therapy simulations. Four patient cases are studied: 
two head-and-neck, one sarcoma near the spine, and one 
breast cancer case. For each irradiation field, the production 
of the following PET isotopes is calculated: 15O, 11C, 10C, 
14O, 30P, 38K, and 13N. The time sequence of the pencil 
beam scanning irradiation, the decay of the PET isotopes 
during the irradiation, and biological washout are included in 
the simulation. The production of these nuclei is then used to 
calculate a PET image for two scan protocols: a scan of 120 
seconds after the first field, or a scan of 120 seconds after 
the last field. To mimic a typical scanner spatial resolution, 
the images are blurred using a Gaussian blurring function 
with 4 mm FWHM.  
Deviations from the treatment plan are simulated by shifting 
the patient 4 mm perpendicular to the field angle, or by 
increasing the patient density by 3%. The PET image is then 
simulated again for each scanning protocol. The ability of 
